<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872766</url>
  </required_header>
  <id_info>
    <org_study_id>15 7714 03</org_study_id>
    <nct_id>NCT02872766</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of Corneal Cross Linking for the Treatment of Myopia.</brief_title>
  <acronym>CXLMyopie</acronym>
  <official_title>A Pilot Evaluation of the Safety and Efficacy of Topographically Customized Corneal Cross Linking for the Treatment of Myopia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avedro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      43 Subjects (43 eyes) qualified for participation will undergo the required screening
      procedures to determine study eligibility. The surgical protocol involves applying riboflavin
      0,22% to 0,25 % up to 20 minutes . Then, the eyes will be exposed to UVA (ultraviolet A)
      light with the KXL II system according to the programmed treatment pattern.

      All use of the KXL II system will be in accordance with the general instructions in the
      operator's manual. All subjects will be evaluated at screening, Day 3, and 1, 3, 6 ,12 and 24
      months after treatment.

      Manual keratometry, manifest refraction, uncorrected visual acuity, best corrected visual
      acuity, slit lamp biomicroscopy, pentacam measurements and placido disc topography (TMS),
      will be obtained at baseline and at appropriate times after the treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Best corrected visual acuity</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 month</time_frame>
    <description>Clinical examination and slit lamp biomicroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical examination and slit lamp biomicroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical examination and slit lamp biomicroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical examination and slit lamp biomicroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Clinical examination and slit lamp biomicroscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uncorrected visual acuity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in manifest refraction spherical equivalent from baseline</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in corneal curvature from baseline</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Corneal cross linking (CXL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to Ultraviolet A light with the KXL II system according to the programmed treatment pattern.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CXL Myopia</intervention_name>
    <description>Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.</description>
    <arm_group_label>Corneal cross linking (CXL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent

          -  Willingness to follow all instructions and comply with schedule for follow up visits

          -  Having myopia with manifest refraction spherical equivalent of -1.00 to -2.50 D, with
             cylindrical component pl to -0.75 D

          -  Social security insurance or equivalent

        Exclusion Criteria:

          -  sensitivity to the use of the test article(s)

          -  hypersensitivity to local anesthesics

          -  Corneal pachymetry that is &lt; 480 microns

          -  Eyes with keratoconus

          -  Eyes which are aphakic or with corneal intacs

          -  Previous ocular condition (other than refractive error) in the eye to be treated that
             may predispose the eye for future complications. For example: History of corneal
             disease (e.g., herpes simplex, recurrent erosion syndrome, corneal dystrophy,
             refractive keratotomy etc.), clinically significant corneal scarring in the
             crosslinking treatment zone

          -  Pregnancy or lactation

          -  Patients with a current condition that, in the investigator's opinion, would interfere
             with or prolong epithelial healing

          -  Taking Vitamin C (ascorbic acid) supplements within 1 week of the cross-linking
             treatment.

          -  Juridical protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>François MALECAZE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura BOGDANOVITCH</last_name>
    <phone>561778437</phone>
    <phone_ext>+33</phone_ext>
    <email>bogdanovitch.l@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François MALECAZE, Pr</last_name>
      <phone>561779999</phone>
      <phone_ext>+33</phone_ext>
      <email>malecaze.f@chu-toulouse.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

